UnitedHealth says needs more information to decide on coverage policy for Biogen's Alzheimer's drug - CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to UnitedHealth says needs more information to decide on coverage policy for Biogen's Alzheimer's drug - CEO
July 16, 2021 8:25 AM EDT
BofA Securities analyst Geoff Meacham lowered the price target on Biogen (NASDAQ: BIIB) to $400.00 (from $415.00) while maintaining a Neutral rating on commercial headwinds.
...
More
July 15, 2021 5:38 PM EDT
(Updated - July 15, 2021 6:00 PM EDT)
Shares of Biogen (NASDAQ: BIIB) are losing 3% after-hours following a unanimous vote by a panel of prominent medical experts claiming the company's recently approved Alzheimer's drug Aduhelm offers no patient benefit.
In a recent meeting held by the... More
July 15, 2021 12:14 PM EDT
Cantor Fitzgerald analyst Steven Halper raised the price target on UnitedHealth Group (NYSE: UNH) to $450.00 (from $425.00) while maintaining an Overweight rating.
The analyst commented, "We reiterate our Overweight rating on UNH shares and increase our 12-month price target to $450 from $425. This morning, July 15, 2021, the company reported 2Q21... More
